Advertisement


Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

2024 ASCO Annual Meeting

Advertisement

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
IMpower010, which looked at adjuvant atezolizumab for patients with completely resected early stage non-small cell lung cancer, we presented the long-term final disease-free survival as well as the second interim overall survival data, now with over 60 months of follow-up. The study had a complex hierarchical statistical design such that first group were those with PD-L1 expression stage 2 to 3A, next group, all stage 2 to 3A, then all comers, including about 12% of patients with 1B, and only if all three of those were met could we formally test overall survival. As was seen in the first interim analysis, the second interim now with the final disease-free survival in that first group with PD-L1 expression stage 2 to 3A remains robust with a hazard ratio of 0.7, translating into nearly a 30-month difference in disease-free survival. In the second group, when we look at all stage 2 to 3A, continue to see a disease-free survival benefit, which does reach statistical significance, hazard ratio of 0.85. But when we bring in that stage 1B, that drops to... Sorry, that was 0.83. ... 0.85, when we bring in that other group, no longer statistically significant. So overall survival could not be formally tested, but we do continue to see this robust disease-free survival benefit, particularly in those with PD-L1 expression. And when we look at those with the highest PD-L1 expression, greater than 50%, that disease-free survival benefit hazard ratio was 0.48. We haven't reached the median for that group of patients. And, in that group, the overall survival hazard ratio was 0.47. However, we can't formally statistically test that because of the way the trial is designed. So in conclusion, when we look at this final disease-free survival result and second interim overall survival result from IMpower010, we do continue to see robust clinical benefit for patients who have gone through surgical resection with early stage lung cancer, stage 2 to 3A, where their tumor expresses PD-L1 expression. And we do believe this continues to be a very reasonable treatment option for that subgroup of patients where there is PD-L1 expression, particularly in those with the highest PD-L1 expression of greater than 50%.

Related Videos

Pancreatic Cancer

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Breast Cancer

Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study

Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).

Advertisement

Advertisement




Advertisement